Harmony Biosciences Holdings, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Harmony Biosciences Holdings, Inc. (HRMY) on April 14, 2026. The filing reports significant changes in executive leadership, specifically the departure of the Chief Financial Officer (CFO) and the immediate appointment of a successor.
Key Financial Metrics
The filing does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on executive compensation arrangements and personnel changes.
Material Changes
- Departure of CFO: Sandip Kapadia stepped down as Chief Financial Officer effective April 14, 2026, to pursue other career opportunities. A Separation Agreement was executed, entitling him to severance payments and benefits per his employment and award agreements in exchange for a release of claims.
- Appointment of CFO: Glenn Reicin was appointed as Chief Financial Officer effective April 14, 2026. Mr. Reicin previously served as Senior Advisor and CFO at Eccogene, Inc., and held CFO roles at Alladapt Immunotherapeutics, Inc. and Sigilon Therapeutics, Inc.
Compensation, Outlook, and Risks
New CFO Compensation Package (Glenn Reicin):
- Base Salary: $500,000 annually.
- Target Bonus: 50% of annual base salary ($250,000), contingent on performance objectives.
- Equity Grant: Stock option award with an aggregate grant date fair value of $3,000,000. Vesting schedule: 25% on the first anniversary, with the remaining 75% vesting quarterly thereafter over the next three years.
- Severance Provisions: In the event of termination without cause or for good reason, Mr. Reicin is entitled to 12 months of base salary, 12 months of healthcare coverage, unpaid bonuses, and outplacement services. In the event of a Change in Control within specific windows, he receives a pro-rata bonus and full accelerated vesting of the stock option.
Risks and Contingencies: The filing notes that severance payments are subject to the execution of a general release of claims and compliance with restrictive covenants. The Employment Agreement includes a "best pay" provision under Section 280G of the Internal Revenue Code to optimize after-tax treatment regarding potential excise taxes on parachute payments.
Investor Verification Checklist
- Review the full text of the Separation Agreement (Exhibit 10.1) to understand the specific severance obligations to the departing CFO.
- Examine the Executive Employment Agreement (Exhibit 10.2) for detailed terms regarding the new CFO's vesting schedule and termination triggers.
- Verify the company's cash position in recent 10-Q or 10-K filings to assess the impact of the new $500,000 base salary and $3,000,000 equity grant on future burn rates.
- Monitor subsequent filings for any interim financial updates or changes in strategic direction following the leadership transition.